What is Resverlogix?
Founded in 2001, Resverlogix is a pioneer in the development of small molecule therapeutics, specifically focusing on bromodomain and extra-terminal (BET) inhibition. Its lead candidate, apabetalone (RVX-208), represents a significant advancement in precision medicine, currently undergoing Phase III clinical trials. The company's research scope is expansive, targeting a diverse array of indications including cardiovascular disease, end-stage renal disease, chronic kidney disease, and various orphan diseases. By addressing the underlying epigenetic mechanisms of these conditions, Resverlogix occupies a unique niche in the biotechnology sector, aiming to provide transformative treatments for patients with high unmet medical needs.
How much funding has Resverlogix raised?
Resverlogix has raised a total of $264M across 13 funding rounds:
Unspecified
$1.8M
Share Placement
$1.7M
Debt
$30M
Share Placement
$36.6M
Share Placement
$10M
Share Placement
$87M
Debt
$30M
Share Placement
$10.3M
Multiple Rounds
$32.2M
Debt
$6M
Unspecified (2011): $1.8M, investors not publicly disclosed
Share Placement (2014): $1.7M supported by NGN BioMed Opportunity II, L.P.
Debt (2014): $30M featuring Citibank
Share Placement (2015): $36.6M backed by Shenzhen Hepalink Pharmaceutical Co., Ltd. and Eastern Capital Limited
Share Placement (2017): $10M with participation from Shenzhen Hepalink Pharmaceutical Co., Ltd and Eastern Capital Limited
Share Placement (2017): $87M led by Shenzhen Hepalink Pharmaceutical Co. Ltd.
Debt (2018): $30M supported by Third Eye Capital
Share Placement (2018): $10.3M, investors not publicly disclosed
Share Placement (2019): $5M backed by Shenzhen Hepalink Pharmaceutical Co. Ltd.
Stock Issuance/Offering (2019): $15.2M, investors not publicly disclosed
Debt (2019): $12M, investors not publicly disclosed
Debt (2021): $6M supported by Shenzhen Hepalink Pharmaceutical Group Co.
Key Investors in Resverlogix
Shenzhen Hepalink Pharmaceutical Co. Ltd.
A global pharmaceutical company specializing in the research, development, and manufacturing of heparin-based products and innovative biopharmaceuticals.
Citibank
A leading global financial services company providing a broad range of corporate and investment banking services to institutions worldwide.
Third Eye Capital
A private investment firm focused on providing creative and flexible debt financing solutions to companies in transition or growth phases.
What's next for Resverlogix?
Looking ahead, the strategic focus for Resverlogix remains the successful completion of its ongoing Phase III clinical trials and the subsequent pursuit of regulatory approvals. The recent infusion of capital provides the necessary runway to finalize these critical studies and prepare for potential commercial launch strategies. As the company transitions from a research-heavy entity to a potential commercial-stage pharmaceutical player, the integration of its BET inhibitor technology into standard care protocols will be the primary driver of long-term shareholder value. Continued collaboration with strategic partners will likely remain a cornerstone of its operational roadmap as it seeks to validate the clinical efficacy of apabetalone across its broad therapeutic portfolio.
See full Resverlogix company page
